Navigation Links
Cethrin in Medical News

Alseres Shares Begin Trading on the Pink Sheets OTC Market

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...

Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology

...ed in December 2006 and amended in March 2007 (the cethrin License) was further amended. The Amendment repla...nd performance-related milestones contained in the cethrin License with a formula-based approach to sharing a...nt for the compounds and technology covered by the cethrin License. In the event that the Company fails to s...

Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice - 508-497-2360 ext. 226 Alseres Pharmaceu...

Alseres Pharmaceuticals, Inc. Announces $200,000 Financing

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...

Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia Alseres Pharmaceuticals, Inc 50...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...ing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pha...

Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call

...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals,...

Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference

...yndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...

Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results

...ful, this trial will provide us with evidence that cethrin is more effective than a placebo in treating acute...ur preliminary planning for the Phase IIb trial of cethrin called for us to enroll up to 100 subjects in 80 s...ropriate sites and investigators for the Phase IIb cethrin study expected to commence in the first quarter of...

Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call

...providing the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres Pharmaceuticals...
Cethrin in Medical Technology

Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons

Company Announces Extension of Phase I/IIa Trial to 9 mg Dosage Level HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ -- Boston Life Sciences announced today that clinical data on its lead nerve repair therapy, Cethrin(R), were presented in the Neurotrauma and Critical Care Scientific Sess...

Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia - 508-497-2360 ext. 224 Alseres ...

Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury

... Analysis of the data by dose group indicates that cethrin doses of 1 and 3 mg appear to be the most benefici... ) "The safety and efficacy observations of the cethrin trial continue to be encouraging. Many patients ha...orward with its previously announced plans for the cethrin Phase IIb trial in acute spinal cord injury in the...

Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates

...eres may exercise an option to amend the Company's cethrin License Agreement. (Logo: http://www.newscom.co...ard for Alseres in realizing the full value of our cethrin spinal cord program and our Rho inhibitor technolo...cts in a Phase I/IIa clinical trial indicated that cethrin was safe and well tolerated. The overall populatio...

Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program

...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and ALTROPANE are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext 224 scorreia@alseres.com or ...

Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008

...ark Hurtt, Chief Medical Officer, will discuss the cethrin development program as a member of an expert panel...ion, Dr. Hurtt will present interim results of the cethrin Phase I/IIa clinical trial in acute spinal cord in...acy results from the first 37 patients in Alseres' cethrin Phase I/IIa study. The data indicated that...

Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury

...ed enrollment in the Phase I/IIa clinical trial of cethrin in acute spinal cord injury (SCI). A total of 48 s...iously announced plans for the placebo-controlled, cethrin Phase IIb trial in acute spinal cord injury at sit...rope and other countries in 2008. "We believe that cethrin continues to be the most advanced drug candidate i...

Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial

... DSMB's recommendation is an important step in the cethrin clinical plan," commented Dr. Mark Hurtt, Alseres'...understanding of the encouraging efficacy data for cethrin at lower doses, and provide additional safety data...ient enrollment in early 2008." About Cethrin(R) cethrin is a recombinant protein drug intended to facilita...
Cethrin in Biological Technology

Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. http://www.alseres.com/ Contact: Kenneth L. Rice 508...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...iding the information in this press release as of this date and assumes no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Ken Rice -- 508-497-2360 ext. 226 Alseres Pharma...

Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results

...8, in Washington, DC by Dr. Michael Fehlings, principal Investigator of the cethrin Phase I/IIa trial. -- We are pursuing development and commercialization p... no obligations to update the information in this press release. Alseres, cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. ...

Alseres Pharmaceuticals, Inc. Raises $5 Million

...rmation in this press release as of this date and assumes no obligations to update the information in this press release. Alseres is a trademark and cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc. Contact: Sharon Correia -- 508-497-2360 ext. 224 Alseres Pharmaceut...

Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights

...d Injury on the first 37 subjects treated with cethrin at doses up to 6 mg. The data indicated that cethrin was safe and well tolerated. The overall population of patients treated with cethrin demonstrated an improvement in their impairmen...

Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference

...tegies, plans or prospects regarding the future, including the Company's clinical development and trials for CETHRIN, the prospects of FDA approval of cethrin and the commercialization, including partnering opportunities, of CETHRIN. Forward- looking statements can be identified by terminology such as "antic...

Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference

...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...

Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting

...cted in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the t...
Other Tags
(Date:9/1/2015)... ... 2015 , ... A new episode of “Voices In America”, hosted by famous ... topic of arthritis. There are over 100 different types of arthritis. One of the ... in an effort to shed light on this important topic. , Anyone who is ...
(Date:9/1/2015)... ... , ... The premier online medical education company for Podiatrists ... podiatric, surgical and wound care conferences . The Residency Education Summits standardize ... the podium and across the table during hands-on surgical and advanced wound care ...
(Date:8/31/2015)... Orange, NJ (PRWEB) , ... September 01, 2015 ... ... the spine to eliminate chronic back pain – once required a long, arduous ... a shorter hospital stay, less pain, less blood loss and minimal muscle damage. ...
(Date:8/31/2015)... ... August 31, 2015 , ... ITC ... wealth of information for specific translation services within the medical and pharmaceutical industries. ... track record of successful work. , ITC Global Translations specializes in professional translation ...
(Date:8/31/2015)... ... , ... In an article based on a reader’s question that ... of treating back pain caused by a disrupted disk by using steroids rather than ... function in patients suffering from a herniated disk, the level of pain that patients ...
Breaking Medicine News(10 mins):Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
Other Contents